Diagnostyka

Diagnostyka EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Diagnostyka (DIA.WA) as of Nov 1, 2026 is 383.66 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 498.78 M PLN — a change of -23.08% (lower).

EBITDA

383.66 MPLN

YoY

-23.08%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Diagnostyka is 2025 383.66 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Diagnostyka was 2024 498.78 M PLN. It decreases by -23.08% lower compared to the previous year.

The Diagnostyka EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
687.51 M PLN
Jan 1, 2022
252.04 M PLN
Jan 1, 2023
380.67 M PLN
Jan 1, 2024
498.78 M PLN
Jan 1, 2025
383.66 M PLN
The Diagnostyka EBITDA history
YEAREBITDAYoY
383.66 MPLN-23.08%
498.78 MPLN+31.03%
380.67 MPLN+51.04%
252.04 MPLN-63.34%
687.51 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnostyka Stock analysis

What does Diagnostyka do? Diagnostyka SA generates revenue through its network of 180 laboratories and 1,100 Sampling Labs across Poland, offering over 3,000 test types including hematology, infection diagnostics, allergology, and hormonal diagnostics. The company provides both routine and specialist laboratory services, with tests available with or without a physician's referral, catering to individual patients and healthcare providers. Its specialization in molecular biology, autoimmune diagnostics, and blood collection drives demand from private individuals seeking direct access to medical analysis without a doctor's prescription. The firm's revenue model relies on a comprehensive service chain from biological material collection and transportation to final analysis results, serving a broad customer base including patients, clinics, and hospitals. With a focus on accessible diagnostics, Diagnostyka SA expands its market reach through its extensive lab network, enabling widespread availability of medical testing services throughout Poland. The company's ability to deliver specialized tests like molecular biology and autoimmune diagnostics differentiates its offerings in the healthcare sector. Diagnostyka is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnostyka stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Diagnostyka is 383.66 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Diagnostyka changed from 498.78 M PLN to 383.66 M PLN, representing a -23.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Diagnostyka since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Diagnostyka historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Diagnostyka

All Key Metrics — Diagnostyka